Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Narrative) (Details)

v3.5.0.2
Notes Payable (Narrative) (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Jul. 01, 2016
Jun. 22, 2016
USD ($)
May 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Aug. 01, 2016
USD ($)
Jun. 28, 2016
Apr. 07, 2016
May 31, 2015
USD ($)
May 15, 2015
USD ($)
Jul. 31, 2012
USD ($)
Debt Instrument [Line Items]                            
Compounded interest on notes payable       $ 352,000 $ 429,000 $ 1,176,931 $ 429,074              
Notes payable       61,200,000   61,200,000                
Change in fair value of financial instruments       1,469,928 (1,852,730) 2,595,287 (125,627)              
Lymphoseek sales revenue       4,231,719 1,963,548 8,014,399 3,798,970 $ 10,300,000            
Net interest expense       7,500,000 1,600,000 9,700,000 2,500,000              
Interest expense recorded related to amortization       5,000 146,000 $ 77,964 358,924              
R-NAV [Member]                            
Debt Instrument [Line Items]                            
Joint venture, effective date of termination           May 31, 2016                
Remaining amount on promissory note forgiven     $ 333,333                      
Cardinal Health [Member]                            
Debt Instrument [Line Items]                            
Percentage of receivables due from customers                   50.00%        
Remaining percentage of receivables due from customers held in escrow account                   50.00%        
Subsequent Event [Member] | Cardinal Health [Member]                            
Debt Instrument [Line Items]                            
Percentage of receivables due from customers                 75.00%          
Remaining percentage of receivables due from customers held in escrow account                 25.00%          
Percentage of receivables due from customers after reaching escrow account limit                 100.00%          
Subsequent Event [Member] | Cardinal Health [Member] | Maximum [Member]                            
Debt Instrument [Line Items]                            
Escrow account threshold target amount                 $ 1,000,000          
Platinum Credit Facility [Member]                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity, amount                           $ 50,000,000
Current borrowing capacity                           $ 35,000,000
Compounded interest on notes payable           $ 624,000                
Debt instrument effective rate           In accordance with the terms of the Section 16(b) Settlement Agreement discussed in Note 15(c), Platinum agreed to forgive interest owed on the credit facility in an amount equal to 6%, effective July 1, 2016.                
Notes payable       9,100,000   $ 9,100,000                
Remaining borrowing capacity       27,300,000   27,300,000                
Unused additional borrowing capacity       15,000,000   15,000,000                
Platinum notes payable       417,000   417,000                
Change in fair value of financial instruments       (1,500,000) $ 1,900,000 (2,600,000) $ 126,000              
Estimated fair value       9,500,000   9,500,000                
Platinum Credit Facility [Member] | Subsequent Event [Member]                            
Debt Instrument [Line Items]                            
Percentage of interest forgiven on credit facility 6.00%                          
Capital Royalty Partners II LP [Member]                            
Debt Instrument [Line Items]                            
Compounded interest on notes payable           553,000                
Notes payable       51,700,000   $ 51,700,000                
Debt instrument face amount                       $ 50,000,000    
Debt instrument, unused borrowing capacity                       $ 10,000,000    
Payment terms           2 years                
Debt discount related to lender fees and other costs                         $ 2,200,000  
End-of-term fee amount       1,000,000   $ 1,000,000             1,000,000  
Minimum amount of yearly EBITDA required under agreement           5,000,000                
Minimum sales revenue target           $ 22,500,000   11,000,000            
Minimum sales revenue target in 2020                         45,000,000  
Cure right ratio           2.5                
Liquidity minimum       $ 5,000,000   $ 5,000,000             $ 5,000,000  
Debt instrument default interest rate percentage       18.00%   18.00%         18.00%      
Reduced minimum sales revenue target in 2015               $ 10,000,000            
Obligations under loan agreement due and payable     $ 56,157,240.69                      
Claims made from primary bank accounts on default   $ 4,100,000                        
Cash adjusted to collection of collateral, on claims of default   778,000       $ 778,000                
Cash adjusted to prepayment premium, on claims of default   2,100,000       2,100,000                
Cash adjusted to backend facility fee, on claims of default   1,000,000                        
Cash adjusted to principal balance of debt on default   $ 189,000                        
Notes payable, discounts       $ 2,000,000   2,000,000                
Capital Royalty Partners II LP [Member] | Accrued Liabilities and Other [Member]                            
Debt Instrument [Line Items]                            
Accrued interest       $ 2,300,000   $ 2,300,000